Literature DB >> 25695397

A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.

Troy J Kemp1, Ken Matsui, Gloriana Shelton, Mahboobeh Safaeian, Ligia A Pinto.   

Abstract

To assess immunogenicity and development of antibodies in the context of vaccination, it is critical to quantify titers of neutralizing antibodies. We have been employing the 293TT cell-based neutralization assay system to quantify anti-HPV neutralizing antibodies. In this system, human papillomavirus (HPV) pseudovirion (PsV) particles encapsidating secreted alkaline phosphatase (SEAP) gene are used to measure infection of 293TT cells in 72-hr cell-culture supernatants. SEAP has traditionally been measured by Great EscAPe™ SEAP Chemiluminescence Kit 2.0 (GE). To reduce the cost, and to potentially increase efficiency, we sought a cheaper kit with better detection capability. Performance characteristics of the newer chemiluminescence kit, ZiVa® Ultra SEAP Plus Assay (Ziva) and GE were compared using the 293TT system. Dose titration of HPV PsV 16 or 18 showed that signal-to-noise ratios at 48 and 72 hr post-infection were higher for ZiVa at nearly all doses. ZiVa was superior to GE as it was able to detect SEAP at 48 hr, as well as when lower numbers of 293TT cells were used. The ability of ZiVa to quantitate HPV-16 and -18 neutralizing antibody titers was tested using sera from Cervarix® immunized individuals. Spearman rank correlational analyses showed excellent correlations between the titers obtained with ZiVa and GE for anti-HPV16 (r = 0.9822, p < 0.0001) and anti-HPV18 (r = 0.9832, p < 0.0001) antibodies. We concluded that ZiVa is superior to GE in detecting SEAP, and the antibody titers in sera of vaccinated individuals were similar to those obtained with GE. Thus, Ziva is a suitable alternative to GE.

Entities:  

Keywords:  Cervarix®; ELISA, enzyme-linked immunosorbent assay; GE, Great EscAPe™ SEAP Chemiluminescence Kit 2.0; GFP, green fluorescent protein; Gardasil®; HPV, human papillomavirus; L1 and L2, late 1 and late 2 proteins; PsV, pseudovirion; RLU, relative-light-unit; SEAP; VLP, virus-like-particle; ZiVa; ZiVa, ZiVa Ultra SEAP Plus Assay; human papillomavirus; vaccine

Mesh:

Substances:

Year:  2015        PMID: 25695397      PMCID: PMC4514413          DOI: 10.4161/21645515.2014.990851

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  38 in total

Review 1.  Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel.

Authors:  W Cates
Journal:  Sex Transm Dis       Date:  1999-04       Impact factor: 2.830

2.  Maturation of papillomavirus capsids.

Authors:  Christopher B Buck; Cynthia D Thompson; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

Authors:  Diana V Pastrana; Ratish Gambhira; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Timothy D Culp; Neil D Christensen; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  Virology       Date:  2005-07-05       Impact factor: 3.616

4.  Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®).

Authors:  Troy J Kemp; Mahboobeh Safaeian; Allan Hildesheim; Yuanji Pan; Kerri J Penrose; Carolina Porras; John T Schiller; Douglas R Lowy; Rolando Herrero; Ligia A Pinto
Journal:  Vaccine       Date:  2012-10-31       Impact factor: 3.641

5.  In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids.

Authors:  K Kawana; H Yoshikawa; Y Taketani; K Yoshiike; T Kanda
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

6.  Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.

Authors:  Mahboobeh Safaeian; Troy J Kemp; David Yuanji Pan; Carolina Porras; Ana Cecilia Rodriguez; Mark Schiffman; Bernal Cortes; Hormuzd Katki; Sholom Wacholder; John T Schiller; Paula Gonzalez; Kerri Penrose; Douglas R Lowy; Wim Quint; Leen-Jan van Doorn; Rolando Herrero; Allan Hildesheim; Ligia A Pinto
Journal:  Hum Vaccin Immunother       Date:  2013-04-09       Impact factor: 3.452

7.  Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Authors:  Mahboobeh Safaeian; Carolina Porras; Yuanji Pan; Aimee Kreimer; John T Schiller; Paula Gonzalez; Douglas R Lowy; Sholom Wacholder; Mark Schiffman; Ana C Rodriguez; Rolando Herrero; Troy Kemp; Gloriana Shelton; Wim Quint; Leen-Jan van Doorn; Allan Hildesheim; Ligia A Pinto
Journal:  Cancer Prev Res (Phila)       Date:  2013-11

Review 8.  A review of clinical trials of human papillomavirus prophylactic vaccines.

Authors:  John T Schiller; Xavier Castellsagué; Suzanne M Garland
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

9.  High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses.

Authors:  Peter Sehr; Ivonne Rubio; Hanna Seitz; Kerstin Putzker; Lis Ribeiro-Müller; Michael Pawlita; Martin Müller
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

10.  Optimization of multimeric human papillomavirus L2 vaccines.

Authors:  Subhashini Jagu; Kihyuck Kwak; Balasubramanyam Karanam; Warner K Huh; Vijayarangam Damotharan; Sudha V Chivukula; Richard B S Roden
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more
  1 in total

1.  Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies.

Authors:  Joshua W Wang; Ken Matsui; Yuanji Pan; Kihyuck Kwak; Shiwen Peng; Troy Kemp; Ligia Pinto; Richard B S Roden
Journal:  Curr Protoc Microbiol       Date:  2015-08-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.